drugset / Trial / NCT05135312

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

NCT05135312

Phase 4 Unknown 10 enrolled OptiSkin Medical Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

Timeline

Start
2021-08-09
Primary completion
2022-08-08
Completion
2022-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous